BALTIMORE, Md. – MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new synthetic THC analog with fewer side-effects and novel therapeutic potential compared to cannabis, today announced that management will participate in the Opening Bell Ceremony at the Nasdaq Stock Market on Wednesday, August 9, 2023.
Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals will lead the ceremony alongside other members of the Company’s Board of Directors and management team.
“This Opening Bell Ceremony is a celebration of the hard work and dedication of our team members which enabled us to be on NASDAQ and positioned us for long-term growth,” said Mr. Aminov. “Our initial drug candidate, MIRA1a, is primed for success across multiple indications as the first synthetic cannabinoid therapy that eliminates the negative side effects and impurities found in marijuana extracts. If approved by the FDA, MIRA1a may be a significant advancement in treating anxiety, cognitive decline, and chronic pain for the countless sufferers who are well aware of the ineffectiveness and burden of living with side effects that have come along with decades of flawed solutions. And unlike marijuana and opiates, MIRA1a is not and will not have the restrictions of a controlled substance. I look forward to our company’s journey ahead as a NASDAQ company.”
The Opening Bell Ceremony will be broadcast live starting at 9:15 a.m. Eastern Time from the NASDAQ MarketSite Tower in New York, NY. To view the broadcast, please visit: www.nasdaq.com/marketsite/bell-ringing-ceremony.
About MIRA Pharmaceuticals Inc.
We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Our target patient population is also typically presenting with chronic pain. Our drug candidate, MIRA1a, if approved by the FDA, may be a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by us, we believe that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain by potentially striking a balance between the beneficial effects of THC and CBD.
Additional information about the Company is available at: www.mirapharmaceuticals.com.